ISSN 1662-4009 (online)

ey0019.8-6 | Important for Clinical Practice | ESPEYB19

8.6. Characteristics of growth in children with classic Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency during adrenarche and beyond

T Troger , G Sommer , M Lang-Muritano , D Konrad , B Kuhlmann , U Zumsteg , CE Fluck

J Clin Endocrinol Metab. 2022; 107(2): e487-e499. PMID: 34599587https://pubmed.ncbi.nlm.nih.gov/34599587/Brief Summary: This study describes the growth of adequately treated children with classical Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency during adrenarche and beyond. Patients with and without significant bone age advancement, and thus differing height prediction...

ey0020.6-9 | New Concerns | ESPEYB20

6.9. Leukocyte telomere length in children with congenital adrenal hyperplasia

C Raftopoulou , O Abawi , G Sommer , M Binou , G Paltoglou , CE Fluck , ELT van den Akker , E Charmandari

Brief summary: This prospective observational cohort study determined leukocyte telomere length (LTL) in 76 patients with genetically confirmed CAH (83% classic CAH). LTL was shorter in patients with classic vs nonclassic CAH, in overtreated than in optimally treated patients, and patients receiving prednisolone compared with hydrocortisone.Telomeres are tandem repeats of a noncoding hexameric nucleotide sequence (5′-TTAGGG-3′) located at the...

ey0018.4-6 | Growth Hormone Therapy: Safety | ESPEYB18

4.6. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study

L Savendahl , R Cooke , A Tidblad , D Beckers , G Butler , S Cianfarani , P Clayton , J Coste , ACS Hokken-Koelega , W Kiess , CE Kuehni , K Albertsson-Wikland , A Deodati , E Ecosse , R Gausche , C Giacomozzi , D Konrad , F Landier , R Pfaeffle , G Sommer , M Thomas , S Tollerfield , GRJ Zandwijken , JC Carel , AJ Swerdlow

Lancet Diabetes Endocrinol. 2020;8(8):683–692. doi: 10.1016/S2213-8587(20)30163-7. PMID: 32707116SAGhE is a large independent European consortium including eight different countries (Belgium, France, Germany, Italy, The Netherlands, Sweden, Switzerland, and the UK) which was set up to evaluate the long-term safety of rhGH in a large cohort (>24 000) of young adult patients t...

ey0020.7-14 | Long-Term Surveillance for Endocrine Complications in Childhood Cancer Survivors | ESPEYB20

7.14. Hypothalamic-pituitary and other endocrine surveillance among childhood cancer survivors

L van Iersel , RL Mulder , C Denzer , LE Cohen , HA Spoudeas , LR Meacham , E Sugden , AYN Schouten-van Meeteren , EW Hoving , RJ Packer , GT Armstrong , S Mostoufi-Moab , AM Stades , D van Vuurden , GO Janssens , C Thomas-Teinturier , RD Murray , N Di Iorgi , SJCMM Neggers , J Thompson , AA Toogood , H Gleeson , C Follin , E Bardi , L Torno , B Patterson , V Morsellino , G Sommer , SC Clement , D Srivastava , CE Kiserud , A Fernandez , K Scheinemann , S Raman , KCJ Yuen , WH Wallace , LS Constine , R Skinner , MM Hudson , LCM Kremer , W Chemaitilly , HM van Santen

Brief summary: In this extensive and updated review, the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) report expert consensus-based guidelines that harmonize recommendations for surveillance of endocrine disorders in childhood cancer survivors.This interdisciplinary panel of 42 international experts formulated new surveillance recommendations for hypothalamic–pituitary (HP) dysfunction. Existing IGHG surveillan...